Cambria Investment Management L.P. Takes Position in Johnson & Johnson $JNJ

Cambria Investment Management L.P. purchased a new position in Johnson & Johnson (NYSE:JNJ) in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 3,005 shares of the company’s stock, valued at approximately $557,000.

Several other institutional investors also recently bought and sold shares of JNJ. Vanguard Group Inc. increased its holdings in Johnson & Johnson by 1.3% in the 2nd quarter. Vanguard Group Inc. now owns 237,047,859 shares of the company’s stock worth $36,209,060,000 after acquiring an additional 3,085,180 shares in the last quarter. Geode Capital Management LLC grew its position in shares of Johnson & Johnson by 2.1% in the second quarter. Geode Capital Management LLC now owns 60,609,476 shares of the company’s stock valued at $9,227,988,000 after purchasing an additional 1,225,676 shares during the period. Norges Bank purchased a new stake in shares of Johnson & Johnson during the second quarter worth about $4,877,174,000. Bank of New York Mellon Corp lifted its stake in Johnson & Johnson by 3.5% in the 3rd quarter. Bank of New York Mellon Corp now owns 24,637,649 shares of the company’s stock valued at $4,568,313,000 after buying an additional 835,146 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its holdings in Johnson & Johnson by 0.3% in the 2nd quarter. Charles Schwab Investment Management Inc. now owns 18,951,337 shares of the company’s stock worth $2,894,979,000 after buying an additional 52,074 shares during the last quarter. 69.55% of the stock is owned by institutional investors and hedge funds.

Johnson & Johnson Trading Down 0.6%

JNJ opened at $245.28 on Thursday. The firm has a market cap of $591.10 billion, a P/E ratio of 22.20, a P/E/G ratio of 2.44 and a beta of 0.34. The company has a quick ratio of 0.77, a current ratio of 1.03 and a debt-to-equity ratio of 0.48. The business has a fifty day simple moving average of $227.06 and a 200-day simple moving average of $203.31. Johnson & Johnson has a 52 week low of $141.50 and a 52 week high of $251.71.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Saturday, January 31st. The company reported $2.46 earnings per share (EPS) for the quarter. Johnson & Johnson had a net margin of 28.46% and a return on equity of 33.04%. The business had revenue of $24.28 billion for the quarter. On average, equities analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 10th. Investors of record on Tuesday, February 24th will be issued a $1.30 dividend. This represents a $5.20 annualized dividend and a yield of 2.1%. The ex-dividend date of this dividend is Tuesday, February 24th. Johnson & Johnson’s dividend payout ratio is 47.06%.

Insider Transactions at Johnson & Johnson

In other news, EVP Timothy Schmid sold 22,623 shares of the firm’s stock in a transaction dated Wednesday, February 18th. The stock was sold at an average price of $244.33, for a total transaction of $5,527,477.59. Following the sale, the executive vice president owned 26,769 shares of the company’s stock, valued at approximately $6,540,469.77. This trade represents a 45.80% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Vanessa Broadhurst sold 6,197 shares of the firm’s stock in a transaction that occurred on Tuesday, February 17th. The stock was sold at an average price of $243.39, for a total transaction of $1,508,287.83. Following the sale, the executive vice president directly owned 23,003 shares in the company, valued at approximately $5,598,700.17. The trade was a 21.22% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 30,142 shares of company stock worth $7,360,528. Company insiders own 0.16% of the company’s stock.

More Johnson & Johnson News

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: FDA Fast Track for nipocalimab in systemic lupus erythematosus — The drug earned Fast Track designation supported by positive Phase 2 data and an ongoing Phase 3 study, which can accelerate review timelines and boosts the pharma pipeline narrative. Nipocalimab Fast Track PR
• Positive Sentiment: New direct-to-consumer drug sales channel — J&J launched a U.S. website to sell certain medications directly to uninsured or out-of-pocket patients, which may expand access and create a new revenue stream outside traditional pharmacy channels. Reuters: Direct-to-consumer site
• Neutral Sentiment: Oncology and other late-stage programs showing progress — Early pasritamig data and other oncology moves underpin higher long-term estimates, but timelines and commercial execution remain key variables. Yahoo: Pipeline & legal update
• Neutral Sentiment: Investor access and upcoming results — J&J scheduled its first-quarter results call for April 14; the call and Q1 metrics will be the next catalysts for guidance and near-term sentiment. Earnings call notice
• Neutral Sentiment: Dividend and income investor interest — J&J continues to be highlighted among top dividend/dividend-growth picks, supporting demand from income-focused investors even amid broader volatility. Dividend aristocrat piece
• Neutral Sentiment: Analyst stance: Hold with limited upside — Bank of America reiterated a Hold rating citing higher oncology-driven estimates but constrained upside, which may temper upside momentum despite pipeline wins. TipRanks: Hold rating
• Negative Sentiment: Bayer legal challenge over prostate cancer product claims — Bayer has initiated legal action related to prostate cancer product claims, introducing litigation risk and potential costs or reputational impact that investors dislike. Yahoo: Legal challenge mention

Wall Street Analyst Weigh In

A number of analysts have commented on JNJ shares. Wolfe Research increased their price objective on shares of Johnson & Johnson from $225.00 to $240.00 and gave the company an “outperform” rating in a report on Monday, January 5th. BMO Capital Markets restated an “outperform” rating on shares of Johnson & Johnson in a research report on Thursday, December 11th. UBS Group reiterated a “buy” rating on shares of Johnson & Johnson in a research report on Monday, January 5th. Daiwa Securities Group upped their target price on Johnson & Johnson from $203.00 to $237.00 and gave the company an “outperform” rating in a report on Thursday, January 29th. Finally, Stifel Nicolaus raised their target price on Johnson & Johnson from $205.00 to $220.00 and gave the stock a “hold” rating in a research note on Thursday, January 22nd. One analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and nine have given a Hold rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $232.70.

About Johnson & Johnson

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.